SALT LAKE CITY and TORONTO, March 11, 2015 (PRNewswire/-) EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a purchase order from its newly-engaged Canadian distributor Preferred Nutrition (www.pno.ca). The company has already received a cash deposit for this initial order.

The first order by Preferred Nutrition was placed for E-drops – the Company’s natural and herbal alternative that helps the body to rid of UTI infections painlessly and effectively without side effects of antibiotics or synthetic drugs.

Preferred Nutrition Inc. is a Canadian premier distribution company founded in 2002. It primarily distributes to approximately 1,200 health food stores across Canada. It represents 5 top product lines for a total of 78 products in the vitamin and supplement category.

Information on EastGate’s natural product line can be found at www.nano-essentials.com Previously, the company announced a distributor for its nutraceutical product line including E-drops in the United States under its own private label.

“We are pleased to have received this purchase order from Preferred Nutrition so soon after their engagement” says Anna Gluskin, EastGate’s CEO. “We look forward to having our products on the shelves of health food stores across Canada and to commence our revenue stream which is a one of the Key Performance Indicators for market analysts and investors, states Ms. Gluskin.

Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Rose Perri 1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com